Latest Market Capitalization News

Paragon Care has lined up an on-market buy-back of up to 82.8 million shares, worth about $10.8 million at the latest closing price, while its employee trust can acquire a further 23.9 million shares. The transactions give the healthcare group two sizeable tools for managing its capital and incentive plans, although neither maximum is guaranteed to be completed.

Tamboran Resources is poised to deliver first gas sales from its Beetaloo Basin pilot project, backed by a robust balance sheet and strategic partnerships aiming to slash drilling costs.

ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.

The Koala Company posted a $24.6 million profit for FY26 on $332.3 million revenue, surpassing IPO forecasts with strong international growth and margin gains.

Lithium Universe Limited has secured $848,452 through the first tranche of a share placement, setting the stage for advancing its Brownsville lithium refinery and innovative recycling technologies.

SkyCity Entertainment Group reported a 22% drop in underlying EBITDA for FY26, impacted by regulatory costs and carded play rollout, while progressing asset sales and preparing for New Zealand's online casino market.

Cogstate Ltd (ASX:CGS) posted a 15.9% rise in profit before tax to US$16.1 million for FY26, driven by a 116% surge in clinical trial sales contracts to $89 million and a 15% revenue increase. The company doubled its final dividend to A$0.04 per share, supported by a strong $118.5 million contracted revenue backlog.

Brazilian Rare Earths (ASX: BRE) has delivered a striking scoping study for its Rocha da Rocha Rare Earths Province in Brazil, anchored by the Monte Alto deposit’s world-class 11.3% TREO grade, projecting robust economics and a low-cost production path.

Helia Group’s half-year profit fell 25% to $100 million, hit by lower premiums and investment income. The insurer declared a combined 43 cents per share dividend and launched a $75 million share buy-back.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

Activeport has raised $3.6 million through an oversubscribed placement led by top-tier investors including Antipodes Partners and Scobie Ward, bolstering its balance sheet to accelerate growth in network automation software.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.